

WHAT IS CLAIMED IS:

- sub B1*
1. ~~A method for cleaving glycation endproducts or cross-linked proteins in an organism, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:
 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid];
 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid];
 L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine];
 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid;
 methylene bis [4,4'-(2-chlorophenylureidophenoxyisobutyric acid)];
 1,1-dimethylbiguanide; and
 5-aminosalicylic acid.~~
 2. The method of claim 1 wherein said compound is 1,4-benzene-bis[4-methyleneamino-phenoxyisobutyric acid].
 3. The method of claim 1 wherein said compound is 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid].
 4. ~~A method of reversing deleterious effects of aging in an organism wherein said effects are formation of glycation endproducts or protein cross-linking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:
 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid];
 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid];
 L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine];
 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid;
 methylene bis [4,4'-(2-chlorophenylureidophenoxyisobutyric acid)];
 1,1-dimethylbiguanide; and
 5-aminosalicylic acid.~~
- sub B2*

11/03/2010 10:52:30 AM

5. The method of claim 4 wherein said compound is 1,4-benzene-bis[4-methyleneamino-phenoxyisobutyric acid].

6. The method of claim 4 wherein said compound is 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid.

7. A method of reversing complications resulting from diabetes wherein said complications result from formation of glycation endproducts or protein cross-linking, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid];
4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid;
L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine];
4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid;
methylene bis [4,4'-(2-chlorophenylureidophenoxyisobutyric acid)];
1,1-dimethylbiguanide; and
5-aminosalicylic acid.

8. The method of claim 7 wherein said compound is 1,4-benzene-bis[4-methyleneamino-phenoxyisobutyric acid].

9. The method of claim 7 wherein said compound is 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid.

10. A method of reversing progress in a patient of rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, or atherosclerosis, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid];

105010" 52652300

33

33

B4
cont

~~4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid;
L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine];
4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic acid;
methylene bis [4,4'-(2-chlorophenylureidophenoxyisobutyric acid)];
1,1-dimethylbiguanide; and
5-aminosalicylic acid.~~

11. The method of claim 10 wherein said compound is 1,4-benzene-bis[4-methyleneamino-phenoxyisobutyric acid].
12. The method of claim 10 wherein said compound is 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid.

T 030403 32052300